Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor
Kenji Ogura1, Takanori Shiga, Masashi Yokochi
1Department of Structural Biology, Graduate School of Pharmaceutical Sciences, Hokkaido University, N12 W6, Sapporo, 060-0812, Japan.
Journal of Biomolecular NMR
|October 3, 2008
Summary
We determined the solution structure of the growth factor receptor-bound protein 2 (Grb2) SH2 domain bound to a novel inhibitor. This reveals key binding interactions for designing improved, high-affinity inhibitors.
Area of Science:
- Biochemistry
- Structural Biology
- Medicinal Chemistry
Background:
- Growth factor receptor-bound protein 2 (Grb2) is a key signaling molecule.
- SH2 domains are crucial for protein-protein interactions in signaling pathways.
- Developing specific inhibitors for SH2 domains is a therapeutic target.
Purpose of the Study:
- To elucidate the solution structure of the Grb2 SH2 domain complexed with a novel macrocyclic inhibitor.
- To compare the solution structure with existing crystal structures and identify discrepancies.
- To provide insights for the rational design of next-generation Grb2 inhibitors.
Main Methods:
- Nuclear Magnetic Resonance (NMR) spectroscopy was employed to determine the solution structure.
- Perdeuterated Grb2 SH2 protein was used for unambiguous assignment of the inhibitor and intermolecular NOEs.
- Comparison was made with X-ray crystallography data.
Main Results:
- A well-defined solution structure of the Grb2 SH2 domain-inhibitor complex was obtained.
- Significant differences were observed compared to crystal structures, particularly regarding domain-swapping and inhibitor binding sites.
- Key binding interactions in solution were identified.
Conclusions:
- The solution structure reveals distinct binding modes compared to crystal structures.
- Understanding these solution-state interactions is critical for accurate inhibitor design.
- This study provides a foundation for developing more potent and specific Grb2 SH2 domain inhibitors.
Related Concept Videos
01:30Assembly of Signaling Complexes
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...